Skip to main content

Table 3 Changes in hemodynamic, blood gas parameters and organ function

From: IgM-enriched immunoglobulins (Pentaglobin) may improve the microcirculation in sepsis: a pilot randomized trial

 Baseline24 h72 hp (time)ap (interaction)b
MAP (mmHg)0.0830.309
 Pentaglobin (n = 10)80 ± 1482 ± 986 ± 15  
 Placebo (n = 9)85 ± 1575 ± 1789 ± 13  
HR (bpm)0.6620.169
 Pentaglobin (n = 10)84 ± 2385 ± 1190 ± 21  
 Placebo (n = 9)95 ± 1989 ± 3080 ± 25  
Norepinephrine tartrate (n, mcg/kg/min)
 Pentaglobin (n = 10)8, 0.13 [0.03–0.39]8, 0.12 [0.03–0.23]7, 0.11 [0–0.38]0.616 
 Placebo (n = 9)8, 0.38 [0.23–0.70]8, 0.50 [0.14–0.70]6, 0.10 [0–0.40]*0.004 
Arterial pH0.1100.377
 Pentaglobin (n = 10)7.43 ± 0.077.42 ± 0.067.45 ± 0.07  
 Placebo (n = 9)7.45 ± 0.037.47 ± 0.057.49 ± 0.07  
PaO2/FiO2 (mmHg)0.8750.474
 Pentaglobin (n = 10)300 ± 89311 ± 151320 ± 89  
 Placebo (n = 9)311 ± 89280 ± 74262 ± 85  
ScvO2 (%)< 0.0010.053
 Pentaglobin (n = 10)80 ± 578 ± 1072 ± 9*  
 Placebo (n = 9)79 ± 968 ± 9**#71 ± 7*  
Base excess (mEq/L)< 0.0010.659
 Pentaglobin (n = 10)0.4 ± 4.92.5 ± 3.85.6 ± 4.9**  
 Placebo (n = 9)1.2 ± 4.74.0 ± 4.85.1 ± 4.4*  
Arterial lactate (mmol/L)
 Pentaglobin (n = 10)1.7 [1.3–3.5]1.5 [1.0–2.2]1.9 [0.9–2.7]0.682 
 Placebo (n = 9)1.6 [1.0–2.2]1.4 [1.0–2.2]1.2 [1.1–1.7]0.755 
Haemoglobin (g/dL)0.4600.356
 Pentaglobin (n = 10)10.4 ± 1.510.5 ± 0.99.6 ± 0.9  
 Placebo (n = 9)9.8 ± 1.810.1 ± 1.310.0 ± 1.1  
Platelets (*103/mmc)0.1700.036
 Pentaglobin (n = 10)158 ± 98141 ± 80153 ± 83  
 Placebo (n = 9)163 ± 86168 ± 84136 ± 67  
Creatinine (mg/dL)0.2840.522
 Pentaglobin (n = 10)1.1 ± 0.71.0 ± 0.50.9 ± 0.4  
 Placebo (n = 9)1.9 ± 1.02.1 ± 1.61.8 ± 1.2  
Bilirubin (mg/dL)
 Pentaglobin (n = 10)0.7 [0.5–1.7]0.8 [0.5–1.6]0.9 [0.5–1.7]0.356 
 Placebo (n = 9)1.0 [0.5–1.3]0.9 [0.5–2.3]0.7 [0.6–2.4]0.515 
Glasgow Coma Scale
 Pentaglobin (n = 10)14 [13–15]15 [13–15]15 [11–15]0.999 
 Placebo (n = 9)14 [10–14]13 [9–14]12 [10–14]0.999 
SOFA score
 Pentaglobin (n = 10)9 [7–11]9 [5–10]7 [6–8]0.229 
 Placebo (n = 9)10 [7–13]12 [6–12]10 [6–12]0.544 
Propofol (mg/kg/h, n)
 Pentaglobin (n = 10)1.2 [0–2.4], 70 [0–2.6], 40 [0–2.6], 40.790 
 Placebo (n = 9)0.8 [0–1.6], 50 [0–1.1], 40 [0–1.6], 30.518 
Remifentanil (mcg/kg/min, n)
 Pentaglobin (n = 10)0.08 [0.04–0.09], 80.05 [0–0.08], 70.06 [0–0.10], 70.366 
 Placebo (n = 9)0.06 [0–0.10], 80.05 [0–0.08], 70.06 [0–0.10], 70.991 
  1. Data are expressed as mean ± standard deviation or median [1st–3rd quartile], as appropriate
  2. MAP mean arterial pressure, HR heart rate, ScvO2 central venous oxygen saturation, SOFA Sequential Organ Failure Assessment
  3. aTwo-way analysis of variance for repeated measures (testing the effect of time) or Friedman test, as appropriate
  4. bTwo-way analysis of variance for repeated measures (testing for the interaction between time and treatment), when applicable
  5. p < 0.05, **p < 0.01 versus baseline, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Friedman test with Dunn’s post hoc test for multiple comparisons, as appropriate
  6. #p < 0.05 versus Pentaglobin group, Two-way analysis of variance for repeated measures with Sidack’s post hoc test or Mann–Whitney U test, as appropriate